Clinical trial
High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor…
NCT00231582 · Assistance Publique - Hôpitaux de Paris, Other · Completed
Key facts
| NCT number | NCT00231582 |
|---|---|
| Title | High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II |
| Official title | Sequential High-Dose Chemotherapy Combining Two Mobilization and Cyto-Reductive Treatments Followed by Three High-Dose Chemotherapy Regimens Supported by Autologous Stem Cell Transplantation |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris, Other |
| Collaborators | Ministry of Health, France Amgen Industry Baxter Healthcare Corporation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Testicular Neoplasms |
| Intervention type | Drug, Procedure |
| Interventions | epirubicin, high-dose and autologous stem cell transplantation, paclitaxel, etoposide, ifosfamide, carboplatin |
| Enrollment | 50 |
| Start date | Sep 1, 2004 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Oct 4, 2005 |
| Last update posted | Feb 25, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: